MorphoSys AG (MOR)
17.51
+0.10
(+0.57%)
USD |
NASDAQ |
May 01, 16:00
17.50
0.00 (0.00%)
After-Hours: 20:00
MorphoSys Research and Development Expense (Quarterly): 86.49M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 86.49M |
| September 30, 2023 | 68.81M |
| June 30, 2023 | 62.16M |
| March 31, 2023 | 89.22M |
| December 31, 2022 | 96.13M |
| September 30, 2022 | 78.37M |
| June 30, 2022 | 64.89M |
| March 31, 2022 | 72.99M |
| December 31, 2021 | 99.51M |
| September 30, 2021 | 75.93M |
| June 30, 2021 | 48.82M |
| March 31, 2021 | 40.15M |
| December 31, 2020 | 62.91M |
| September 30, 2020 | 39.97M |
| June 30, 2020 | 34.03M |
| March 31, 2020 | 23.72M |
| December 31, 2019 | 36.73M |
| September 30, 2019 | 28.82M |
| June 30, 2019 | 27.69M |
| March 31, 2019 | 28.05M |
| December 31, 2018 | 51.81M |
| September 30, 2018 | 20.94M |
| June 30, 2018 | 30.82M |
| March 31, 2018 | 21.09M |
| December 31, 2017 | 40.21M |
| Date | Value |
|---|---|
| September 30, 2017 | 39.67M |
| June 30, 2017 | 24.77M |
| March 31, 2017 | 24.41M |
| December 31, 2016 | 37.94M |
| September 30, 2016 | 24.72M |
| June 30, 2016 | 20.36M |
| March 31, 2016 | 20.55M |
| December 31, 2015 | 27.99M |
| September 30, 2015 | 21.30M |
| June 30, 2015 | 21.25M |
| March 31, 2015 | 16.56M |
| December 31, 2014 | 18.96M |
| September 30, 2014 | 23.05M |
| June 30, 2014 | 16.70M |
| March 31, 2014 | 15.36M |
| December 31, 2013 | 18.05M |
| September 30, 2013 | 17.43M |
| June 30, 2013 | 15.35M |
| March 31, 2013 | 14.52M |
| December 31, 2012 | 11.31M |
| September 30, 2012 | 10.92M |
| June 30, 2012 | 13.21M |
| March 31, 2012 | 13.02M |
| December 31, 2011 | 18.87M |
| September 30, 2011 | 19.26M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
23.72M
Minimum
Mar 2020
99.51M
Maximum
Dec 2021
59.86M
Average
62.91M
Median
Dec 2020
Research and Development Expense (Quarterly) Benchmarks
| Incyte Corp | 429.26M |
| Novartis AG | 2.421B |
| Immatics NV | 35.83M |
| Affimed NV | 20.09M |
| InflaRx NV | 8.688M |